Patents Assigned to Cor Therapeutics, Inc.
-
Publication number: 20040072757Abstract: Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.Type: ApplicationFiled: November 13, 2003Publication date: April 15, 2004Applicant: COR Therapeutics, Inc.Inventors: David L. Wolf, Uma Sinha
-
Publication number: 20030228307Abstract: The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.Type: ApplicationFiled: May 16, 2003Publication date: December 11, 2003Applicants: COR Therapeutics Inc., Millennium Pharmaceuticals Inc.Inventors: Vanitha Ramakrishnan, Maria Amelia Escobedo, Larry J. Fretto
-
Publication number: 20030162690Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described Compositions containing such compounds are also described The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disordersType: ApplicationFiled: April 22, 2002Publication date: August 28, 2003Applicant: COR Therapeutics, Inc.Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
-
Publication number: 20030135036Abstract: This invention relates to the glycoprotein v gene. Specifically, this invention discloses the sequence and structure of the glycoprotein v gene and the amino acid sequence of the glycoprotein v polypeptide. In addition, the evolutionary relationship of the glycoprotein v gene with other glycoproteins is described and several uses of the isolated glycoprotein v gene are shown.Type: ApplicationFiled: August 6, 2002Publication date: July 17, 2003Applicant: COR Therapeutics Inc., a corporation of the State of CaliforniaInventors: Francois Lanza, David R. Phillips, Jean-Pierre Cazenave
-
Publication number: 20030059852Abstract: The present invention discloses that phosphorylation of cytoplasmic tyrosine residues in the &bgr;-subunit of integrins is needed for signal protein association. The invention provides methods of identifying signaling partners involved in integrin mediated signaling, methods of identifying agents which block integrin mediated signaling, methods of using agents which block integrin mediated signaling to modulate biological and pathological processes, and agents which block integrin mediated signaling.Type: ApplicationFiled: March 8, 2001Publication date: March 27, 2003Applicant: COR Therapeutics, Inc.Inventors: David R. Phillips, Deborah Ann Law, Lisa Nannizzi Alaimo
-
Publication number: 20030018184Abstract: Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.Type: ApplicationFiled: April 23, 2002Publication date: January 23, 2003Applicant: COR THERAPEUTICS, INC.Inventors: Johan Sundelin, Robert M. Scarborough
-
Publication number: 20020164698Abstract: The present invention provides the amino acid and nucleotide sequence of a protein that binds to &bgr;3 integrins, &agr;IIb and Src kinase and is involved in integrin mediated signaling.Type: ApplicationFiled: November 26, 2001Publication date: November 7, 2002Applicant: COR Therapeutics, Inc.Inventors: Shengfeng Li, David R. Phillips
-
Publication number: 20020137174Abstract: A DNA sequence encoding a human adenylyl cyclase is described.Type: ApplicationFiled: February 11, 2002Publication date: September 26, 2002Applicant: COR Therapeutics, Inc.Inventors: Daniel R. Storm, Beth Hacker, James E. Tomlinson
-
Publication number: 20020086975Abstract: Novel purinergic receptors are provided, having research, diagnostic and therapeutic applications. Also provided are nucleic acids encoding these receptors, as well as expression systems for their production.Type: ApplicationFiled: September 7, 2001Publication date: July 4, 2002Applicant: COR THERAPEUTICS, INC.Inventors: Pamela B. Conley, Hans-Michael Jantzen
-
Patent number: 6399627Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: GrantFiled: February 11, 2000Date of Patent: June 4, 2002Assignee: Cor Therapeutics, Inc.Inventors: Yonghong Song, Bing-Yan Zhu, Robert M. Scarborough, Lane Clizbe, Zhaozhong Jon Jia, Ting Su, Willy Teng
-
Patent number: 6376515Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: GrantFiled: February 28, 2001Date of Patent: April 23, 2002Assignee: COR Therapeutics, Inc.Inventors: Bing-Yan Zhu, Penglie Zhang, Lingyan Wang, Wenrong Huang, Erick A. Goldman, Wenhao Li, Jingmei Zuckett, Yonghong Song, Robert M. Scarborough
-
Patent number: 6372475Abstract: A DNA sequence encoding a human adenylyl cyclase is described. The amino acid sequence of the adenylyl cyclase is also described.Type: GrantFiled: December 29, 1999Date of Patent: April 16, 2002Assignees: Cor Therapeutics Inc., University of WashingtonInventors: Daniel R. Storm, Beth Hacker, James E. Tomlinson
-
Patent number: 6369063Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: GrantFiled: April 13, 1998Date of Patent: April 9, 2002Assignee: Cor Therapeutics, Inc.Inventors: Ting Su, Bing-Yan Zhu, Robert M. Scarborough
-
Patent number: 6369080Abstract: Novel compounds of formula I: including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.Type: GrantFiled: October 10, 1997Date of Patent: April 9, 2002Assignee: COR Therapeutics, Inc.Inventors: Bing-Yan Zhu, Robert M. Scarborough
-
Patent number: 6333321Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: GrantFiled: August 11, 1998Date of Patent: December 25, 2001Assignee: COR Therapeutics, Inc.Inventor: Robert Scarborough
-
Patent number: 6297026Abstract: Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.Type: GrantFiled: June 7, 1995Date of Patent: October 2, 2001Assignee: Cor Therapeutics Inc.Inventors: Johan Sundelin, Robert M. Scarborough
-
Patent number: 6291469Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I): wherein Q, L, Ai, Bj, R0, R3, R10, m, n, p and q are as defined in the disclosure, which are useful in inhibiting of platelet aggregation.Type: GrantFiled: October 5, 1998Date of Patent: September 18, 2001Assignees: Eli Lilly and Company, COR Therapeutics Inc.Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Kenneth J. Ruterbories, Michael Paal, Gerd Ruhter, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
-
Patent number: 6262047Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: GrantFiled: October 10, 1997Date of Patent: July 17, 2001Assignee: COR Therapeutics, Inc.Inventors: Bing-Yan Zhu, Robert M. Scarborough
-
Patent number: 6245809Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.Type: GrantFiled: June 8, 1999Date of Patent: June 12, 2001Assignees: Cor Therapeutics Inc., Eli Lilly & CompanyInventors: Robert M. Scarborough, Mark Smyth, Ting Su, Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffry Bernard Franciskovich
-
Patent number: 6245743Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: GrantFiled: May 15, 1998Date of Patent: June 12, 2001Assignee: COR Therapeutics, Inc.Inventors: Charles K. Marlowe, Robert M. Scarborough, Alan M. Laibelman, Uma Sinha, Bing-Yan Zhu